While NewAmsterdam Pharma Company NV has underperformed by -4.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAMS fell by -27.12%, with highs and lows ranging from $27.29 to $14.06, whereas the simple moving average fell by -24.53% in the last 200 days.
On December 30, 2024, H.C. Wainwright started tracking NewAmsterdam Pharma Company NV (NASDAQ: NAMS) recommending Buy. A report published by TD Cowen on May 15, 2024, Initiated its previous ‘Buy’ rating for NAMS. Scotiabank also rated NAMS shares as ‘Sector Outperform’, setting a target price of $35 on the company’s shares in an initiating report dated March 14, 2024. Guggenheim Initiated an Buy rating on January 18, 2024, and assigned a price target of $30. Piper Sandler initiated its ‘Overweight’ rating for NAMS, as published in its report on January 16, 2024. RBC Capital Mkts’s report from October 30, 2023 suggests a price prediction of $25 for NAMS shares, giving the stock a ‘Outperform’ rating.
Analysis of NewAmsterdam Pharma Company NV (NAMS)
To gain a thorough understanding of NewAmsterdam Pharma Company NV’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. Taking into account the quick ratio of the company, currently set at 8.08, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and NAMS is recording an average volume of 988.91K. On a monthly basis, the volatility of the stock is set at 7.20%, whereas on a weekly basis, it is put at 11.23%, with a loss of -17.52% over the past seven days. Furthermore, long-term investors anticipate a median target price of $44.33, showing growth from the present price of $15.16, which can serve as yet another indication of whether NAMS is worth investing in or should be passed over.
How Do You Analyze NewAmsterdam Pharma Company NV Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 48.10%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 48.02% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NAMS shares are owned by institutional investors to the tune of 48.02% at present.
